Surgery Partners,Inc. (NASDAQ:SGRY) Files An 8-K Entry into a Material Definitive Agreement

0

Surgery Partners,Inc. (NASDAQ:SGRY) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.

As previously announced, Surgery Partners,Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger, dated May9, 2017 (the “Original Agreement”) by and among the Company, SP Merger Sub,Inc., a wholly owned subsidiary of the Company (“Merger Sub”), NSH Holdco,Inc., a Delaware corporation (“NSH”), and IPC / NSH, L.P., solely in its capacity as sellers’ representative, to which, among other things, Merger Sub will merge with and into NSH (the “Merger”). to the Original Agreement, the Company agreed to acquire NSH for a $760 million enterprise value, subject to certain adjustments as specified in the Original Agreement.

On July7, 2017, the parties thereto entered into a Letter Amendment to Merger Agreement (the “Merger Agreement Amendment,” and the Original Agreement as amended thereby, the “Merger Agreement”), in order to modify certain of the adjustments to enterprise value contained in the Original Agreement. Under the Merger Agreement Amendment, the parties agreed that, among other things, (i)cash spent by NSH after signing of the Original Agreement on certain professional services expenses and capital expenditures that have been or are approved by the Company (and for capital expenditures, currently capped at a maximum spend of $10 million) shall be included as a positive number in the adjustment to enterprise value for cash of NSH and accordingly treated as if it had not been spent for purposes of that adjustment, (ii)current assets and current liabilities, if any, related to such professional services expenses and capital expenditures shall be excluded from the calculations of current assets and current liabilities of NSH for purposes of the adjustment to enterprise value for working capital, and (iii)any amounts owed related to such professional services expenses and capital expenditures shall be excluded from the adjustment to enterprise value for indebtedness of NSH, in each case as further described in the Merger Agreement.

The foregoing summary of the Merger Agreement Amendment, the Merger Agreement and the Merger does not purport to be complete and is subject to, and qualified in its entirety by the full text of the Merger Agreement Amendment, a copy of which is filed as Exhibit2.1 to this Current Report on Form8-K and the full text of the Original Agreement, a copy of which is filed as Exhibit2.1 to the Company’s Current Report on Form8-K filed May11, 2017, both of which are incorporated into this Item 1.01 by reference herein.

The Merger Agreement Amendment has been included to provide investors with information regarding its terms. It is not intended to provide any other factual information about the Company. The representations, warranties and covenants contained in the Merger Agreement were made only for purposes of the Merger Agreement as of the specific dates therein, were solely for the benefit of the parties to the Merger Agreement, may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures made for the purposes of allocating contractual risk between the parties to the Merger Agreement instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Investors are not third-party beneficiaries under the Merger Agreement and should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the parties thereto or any of their respective subsidiaries or affiliates. Moreover, information concerning the subject matter of representations and warranties may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in the Company’s public disclosures.

Forward-Looking Statements

This report may contain “forward-looking” statements as defined by the Private Securities Litigation Reform Act of 1995 or by the U.S. Securities and Exchange Commission (the “SEC”) in its rules, regulations and releases. These statements include, but are not limited to, the Company’s expectations regarding the Merger, including statements regarding the benefits of the Merger, the anticipated timing of the Merger and the expected closing of the Merger, and the performance of its business and the other non-historical statements. These statements can be identified by the use of words such as “believes,” “anticipates,” “expects,” “intends,” “plans,” “continues,” “estimates,” “predicts,” “projects,” “forecasts,” and similar expressions. All forward looking statements are based on management’s current expectations and beliefs only as of the date of this report and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those discussed in, or implied by, the forward-looking statements, including but not limited to, the risk that the parties are unable to obtain required regulatory approvals, the risk that the parties are unable to satisfy other conditions to the consummation of the Merger, the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement , the risk that the Merger may involve unexpected costs, liabilities or delays, and such other the risks identified and discussed from time to time in the Company’s reports filed with the SEC, including the Company’s most recent Annual Report on Form10-K. Readers are strongly encouraged to review carefully the full cautionary statements described in these reports. Except as required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements to reflect events or circumstances after the date of this report, or to reflect the occurrence of unanticipated events or circumstances.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

ExhibitNo.

Description

2.1

Letter Amendment to Merger Agreement, by and among Surgery Partners,Inc., SP Merger Sub,Inc., NSH Holdco,Inc. and IPC / NSH, L.P., dated as of July7, 2017.*

2.2

Agreement and Plan of Merger by and among Surgery Partners,Inc., SP Merger Sub,Inc., NSH Holdco,Inc. and IPC / NSH, L.P., dated as of May9, 2017 (incorporated herein by reference to Exhibit2.1 to the Company’s Current Report on Form8-K filed May11, 2017).*

*Schedules and/or Exhibits have been omitted to Item 601(b)(2)of Regulation S-K. The Company agrees to furnish a supplemental copy of any omitted schedule to the SEC upon request.

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Surgery Partners,Inc.

By:

/s/ Michael T. Doyle

Michael T. Doyle

Chief Executive Officer

Date: July11, 2017

[ Page]

EXHIBITINDEX

ExhibitNo.

Description

2.1

Letter Amendment to Merger Agreement, by and among Surgery Partners,Inc., SP Merger Sub,Inc., NSH Holdco,Inc. and IPC / NSH, L.P., dated as of July7, 2017.*

2.2

Agreement and Plan of Merger by and among Surgery Partners,Inc., SP Merger Sub,Inc., NSH Holdco,Inc. and IPC / NSH, L.P., dated as of May9, 2017 (incorporated herein by reference to Exhibit2.1 to the Company’s Current Report on Form8-K filed May11, 2017).*

*Schedules and/or Exhibits have been omitted
Surgery Partners, Inc. Exhibit
EX-2.1 2 a17-15150_5ex2d1.htm EX-2.1 Exhibit 2.1   Execution Version   July 7,…
To view the full exhibit click here

About Surgery Partners,Inc. (NASDAQ:SGRY)

Surgery Partners, Inc. is a healthcare services company. The Company operates in three lines of business across the United States: Surgical Facility Services, Ancillary Services and Optical Services. The Company’s Surgical Facility Services segment consists of the operation of ambulatory surgery centers (ASCs) and surgical hospitals, which include its anesthesia services. The Company’s Ancillary Services segment consists of a diagnostic laboratory, a specialty pharmacy and multi-specialty physician practices. The Company’s physician practices include its owned and operated physician practices pursuant to management service agreements. The Company’s optical services segment consists of an optical laboratory, an optical products group purchasing organization and a marketing business. The Company’s optical laboratory manufactures eyewear, while its optical product purchasing organization negotiates volume buying discounts with optical product manufacturers.